期刊
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH
卷 6, 期 1, 页码 46-53出版社
SPRINGER
DOI: 10.1007/s12265-012-9413-4
关键词
Cardiometabolic disease; Induced pluripotent stem cell; Disease modeling; Storage disease
资金
- NIH
- NIH/NHLBI
Cardiometabolic diseases encompass simple monogenic enzyme deficiencies with well-established pathogenesis and clinical outcomes to complex polygenic diseases such as the cardiometabolic syndrome. The limited availability of relevant human cell types such as cardiomyocytes has hampered our ability to adequately model and study pathways or drugs relevant to these diseases in the heart. The recent discovery of induced pluripotent stem (iPS) cell technology now offers a powerful opportunity to establish translational platforms for cardiac disease modeling, drug discovery, and pre-clinical testing. In this article, we discuss the excitement and challenges of modeling cardiometabolic diseases using iPS cell and their potential to revolutionize translational research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据